Abacavir is an antiretroviral medication widely used in the treatment of HIV/AIDS. Belonging to the nucleoside reverse transcriptase inhibitor (NRTI) class, abacavir works by inhibiting the reverse transcriptase enzyme, crucial for the replication of the human immunodeficiency virus (HIV). It is often included as part of combination therapy, known as antiretroviral therapy (ART), to enhance treatment efficacy and reduce the risk of drug resistance. One distinctive aspect of abacavir is its potential to cause hypersensitivity reactions, particularly in individuals carrying a specific genetic marker (HLA-B*5701). Prior to initiating abacavir therapy, genetic testing is recommended to identify individuals at risk of severe reactions. Symptoms of hypersensitivity include fever, rash, gastrointestinal issues, and respiratory distress, and if suspected, abacavir should be discontinued immediately. Abacavir is administered orally and has a favorable safety profile when used appropriately. Regular monitoring of HIV viral load and CD4 cell counts is crucial to assess treatment effectiveness. While the medication does not cure HIV/AIDS, it plays a vital role in suppressing the virus, improving immune function, and enhancing the overall quality of life for individuals living with the disease. Ongoing research continues to explore new antiretroviral strategies and improve the management of HIV/AIDS globally.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : A rare case of meningitis and septicemia due to Streptococcus acidominimus
Percival C Dilla, Region II Trauma and Medical Center, Philippines
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain
Title : Association between cardiometabolic risk factors and COVID-19 severity in patients of a rural tertiary hospital
Percival C Dilla, Region II Trauma and Medical Center, Philippines